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ABSTRACT
The infectious life cycle of human papillomaviruses (HPVs) is tightly linked to keratinocyte differentiation. Evidence suggests 
a sophisticated interplay between host gene regulation and virus replication. Alternative splicing is an essential process for 
host and viral gene expression, and is generally upregulated by serine arginine- rich splicing factors (SRSFs). SRSF activity 
can be positively or negatively controlled by cycles of phosphorylation/dephosphorylation. Here we show that HPV16 infection 
leads to accumulation of the paradigm SRSF protein, SRSF1, in the cytoplasm in a keratinocyte differentiation- specific manner. 
Moreover, HPV16 infection leads to increased levels of cytoplasmic and nuclear phosphorylated SRSF1. SR protein kinase 1 
(SRPK1) phosphorylates SRSF1. Similar to HPV upregulation of SRSF1, we demonstrate HPV upregulation of SRPK1 via the 
viral E2 protein. SRPK1 depletion or drug inhibition of SRPK1 kinase activity resulted in reduced levels of SRSF1, suggesting 
that phosphorylation stabilizes the protein in differentiated HPV- infected keratinocytes. Together, these data indicate HPV infec-
tion stimulates the SRPK1–SRSF axis in keratinocytes.
INTRODUCTION
Human papillomaviruses (HPVs) infect cutaneous and 
mucosal epithelia and cause mainly benign lesions (warts). 
However, a subset of HPVs which infect the anogenital 
epithelia can cause preneoplastic disease, which in rare cases 
can progress to cancers, most notably cervical cancer [1]. The 
most prevalent HPV worldwide is HPV type 16 (HPV16). 
HPV16 is responsible for 55 % of cases of cervical cancer but 
is also associated with over 30 % of oropharyngeal cancers, 
which is particularly prevalent in men [2]. Although much 
is known about the cancer- causing properties of HPV16, 
many aspects of the viral life cycle and its interaction with 
the host epithelial cell (keratinocyte) remain unclear. For 
example, our understanding of how the virus utilizes host 
gene expression mechanisms during its replicative life cycle 
remains incomplete.
HPV16 gene expression is stimulated or repressed at various 
post- transcriptional levels, including RNA splicing and poly-
adenylation [3, 4], mRNA stability, nuclear export and trans-
lation [5]. Cellular RNA processing factors including serine 
arginine- rich (SR) splicing factors (SRSFs) and heterogeneous 
ribonucleoproteins (hnRNPs) have been strongly implicated 
in HPV gene regulation. For example, SRSF1 and SRSF3 can 
stimulate, while hnRNP A1 and hnRNP H can repress, expres-
sion of the viral late mRNAs [4, 6]. Moreover, SRSF2, SRSF3 
and hnRNP A1 can each activate alternative splicing of the early 
E6 and E7 mRNAs [7, 8]. SRSFs have multiple roles in RNA 
biogenesis, including in transcription elongation, splicing, 
nuclear export, mRNA stability and translation [9]. However, 
SRSFs are involved in many other cellular processes such as 
chromatin remodelling, genome stability and maintenance, 
nucleolar stress response, cell cycle progression and apoptosis 
control [10]. SRSFs allow appropriate gene expression in other 
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viruses including herpes simplex virus type 1 (HSV1) [11] and 
human immunodeficiency virus (HIV) [12].
SRSF activity in splicing is determined by cycles of phospho-
rylation/dephosphorylation [13]. Phosphorylation is required 
for nuclear import of SR proteins [14, 15] while dephospho-
rylated SR proteins can accumulate in the cytoplasm due 
to their interaction with mature mRNAs exported from 
the nucleus [16–18]. SR protein phosphorylation is carried 
out in vivo by cyclin- dependent- like kinases (Clks) and SR 
protein- specific kinases (SRPKs) [13]. While Clks are found 
exclusively in the nucleus, SRPKs are present in both nuclear 
and cytoplasmic compartments. SRPK1 can bind nuclear 
Clk1 to promote splicing [19] and can relocate to the nucleus 
upon cell stress, in response to epidermal growth factor (EGF) 
and Akt signalling, and during the cell cycle [20]. SRPKs are 
examples of moonlighting proteins with multiple functions 
[21], because they can phosphorylate a range of proteins that 
do not have roles in RNA processing, for example they control 
metabolic signalling [20] and innate immunity [22].
The SRPKs are important factors controlling replication of 
DNA and RNA viruses. For example, HSV1 ICP27 protein 
interacts with SRPK1, controls SRSF phosphorylation and 
inhibits HSV splicing [23]. SRPK1 and 2 phosphorylation of 
the hepatitis B virus (HBV) core protein is an essential step 
in viral DNA synthesis [24] and SRPKs are used by HBV as 
chaperones in genome packaging [25, 26]. SRPK1 has been 
shown to have antiviral properties through regulating innate 
immunity [22]. In the case of HPVs, several HPV E2 proteins 
(the viral transcription/replication factor) in particular HPV1 
and HPV8 E2, can bind SRPK1 directly [27] but the functional 
consequence of binding is not clear. HPV1 E2 is a substrate of 
SRPK1, while HPV1 E4 can inhibit SRPK1 and thus inhibit 
phosphorylation of SR proteins and HPV E2 [28].
Here we report HPV16 upregulation of SRSF1 phosphoryla-
tion and HPV- associated changes in the subcellular location 
of SRSF1 and its kinase, SRPK1, in infected keratinocytes. 
SRPK1 levels were induced in HPV16- positive differentiated 
keratinocytes. HPV16 E2, which can bind and activate SRSF 
gene expression and splicing [29–31], can stimulate SRPK1 
expression.
METHODS
Cell lines, drug treatment, ectopic expression and 
siRNA knockdown
W12E (clone 20863) [32], NIKS [33] and NIKS16 (clone 
2L) cells [34] were grown in F- medium [32] on mitomycin 
C- treated 3T3 fibroblast feeder layer cells at a seeding ratio 
of 1 : 5 fibroblasts to keratinocytes at a concentration of 
2×105 cells per 100 mm dish. Differentiation was induced by 
culturing to high colony density in the presence of 1.2 mM 
Ca2+ [32]. U2OS cells stably transfected with an empty vector 
(U2OSV) or with a plasmid expressing HPV16 E2 (U2OS 
clones A4, B1) [35, 36], HaCaT cells and HeLa cells were 
grown in Dulbecco's modified Eagle medium (DMEM) with 
10 % FCS (Invitrogen).
Cells were treated with SRPIN340 (Sigma) dissolved in 
DMSO for the stated times. E4 expression plasmid pMV11 
(gift of Prof. John Doorbar, University of Cambridge) was 
transfected into HeLa cells using Lipofectamine 2000 (Invit-
rogen) according to the manufacturer’s protocol. Protein 
expression was examined after 48 h. SRPK1 was small inter-
fering RNA (siRNA)- depleted by transfecting Dharmacon 
SMART- Pool siRNAs in RNAiMax transfection reagent 
(Invitrogen) mixture into undifferentiated NIKS16 cells, and 
then allowing them to differentiate as previously described 
[30]. siGLO was used as a non- target siRNA control and to 
monitor transfection efficiency.
Protein extract preparation and western blotting
Cells were washed twice in PBS at 4 °C and lysed in 2× BOLT 
protein loading buffer (Invitrogen). Protein extracts were 
syringe- passaged through a 22- gauge needle 15 times then 
sonicated in a Sonibath for three 30 s pulses. The samples were 
boiled at 100 °C for 5 min before loading on a 12 % NuPAGE 
gel (Invitrogen) and electrophoresed at 150 V for 1 h in 1× 
MES buffer. Proteins were transferred to a nitrocellulose 
membrane using the iBlot transfer kit and iBlot Gel Transfer 
Stacks (Invitrogen) as per the manufacturer’s instructions. 
Membranes were blocked in 5 % milk powder in PBST (or 
in 2 % BSA TBST for the E6 blot) at room temperature for 
1 h. Membranes were washed three times in PBST (or TBST 
for phosphoproteins) for 5 min each then incubated with 
the following primary antibodies: SRSF1 1 : 1000 (Zymed 
Laboratories, clone 96), SRSF2 1 : 1000 (Abcam), SRPK1 
1 : 500 (BD Transduction Laboratories, clone G211-637), 
α-tubulin 1 : 5000 (Abcam), involucrin 1 : 1000 (Sigma clone 
SY5), GAPDH 1 : 1000 (Biodesign clone 6C5) and HPV16 E2 
antibody 1 : 500 (Santa Cruz TVG271). Monoclonal antibody 
104 (Mab104), which detects phosphorylated SR proteins, was 
prepared from hybridoma supernatants (ATCC CRL-2067) 
and used neat. The blots were incubated in their respective 
antibody for 1 h at room temperature or overnight at 4 °C. 
After 1 h, the blots were washed three times in PBST or TBST 
for 5 min. They were then placed in secondary antibody for 
1 h [HRP- linked goat anti- mouse or goat anti- rabbit (Pierce) 
were used at 1 : 2000 dilution]. Blots were washed three times 
in PBST for 5 min before being incubated with ECL western 
blot substrate. The blots were exposed to X- ray film (Thermo-
Scientific) and processed in an X- Omat processor, or imaged 
using an Odyssey LiCOR CLx infrared imaging system.
Phosphoprotein analysis
Cells were scraped into NP-40 lysis buffer (50 mM Hepes, 
pH 7.5, 50 mM NaCl, 0.1 % NP-40) with fresh protease and 
phosphatase inhibitor cocktails according to the manufac-
turer’s instructions (Roche). Dephosphorylation was carried 
out by incubation with calf intestinal alkaline phosphatase 
(Invitrogen) exactly as described previously [37].
Immunofluorescence microscopy
Cells were grown on sterile coverslips until 90 % confluent, 
then washed three times with PBS. Cells were fixed in 58 mM 
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sucrose/5 % formaldehyde in PBS for 10 min at room tempera-
ture, and permeabilized with 70 % acetone/30 % methanol 
for 5 min at −20 °C. Alternatively, for detection of nuclear 
proteins, permeabilization was carried out with 0.5 % NP-40 in 
PBS for 5 min at room temperature. Coverslips were washed 
three times in PBS and incubated at room temperature for 
1 h with primary antibody in PBS/10 % FCS and then washed 
three times with PBS followed by a final wash with distilled 
H2O. Antibodies were: SRSF1, clone 96, 1 : 250 (Zymed Labo-
ratories); SRSF2, 1 : 250 (Sigma); SRSF7, clone 98, 1 : 25 (kind 
gift of Dr James Stevenin, Strasbourg); SRPK1, 1 : 250 (BD 
Transduction Laboratories); involucrin, 1 : 1000 (Sigma); and 
HPVE4, clone B11, 1 : 300 (kind gift of Prof. John Doorbar, 
University of Cambridge). DAPI and secondary antibodies 
were diluted in blocking solution and added to the cells for 1 h 
protected from the light before six washes in PBS, followed by 
one wash in distilled H2O. Coverslips were mounted on glass 
slides with a glycerol- based mounting medium (Citifluor, 
AF1) and sealed with nail enamel. Samples were examined 
using a Zeiss LSM 710 confocal microscope, and Zen black 
software (Zeiss) was used for capturing images. Image fluo-
rescence was quantified using ImageJ following conversion 
to 8- bit format. Background was subtracted and integrated 
pixel density was calculated. Statisical analysis was carried 
out using Graphpad Prism version 8 software.
RESULTS
SRSF1 subcellular location is controlled by HPV-
infection
We used two models of the HPV16 infectious life cycle, W12 
and NIKS16 keratinocytes. W12E (clone 20683) cells are 
cervical keratinocytes derived from a low- grade cervical lesion 
that contain ~100 episomal copies of the HPV16 genomes 
[32, 38]. NIKS cells are spontaneously immortalized foreskin 
keratinocytes [33], and NIKS16 cells (clone 2L) are NIKS cells 
stably transfected with episomal HPV16 genomes [33, 34]. 
These three cell lines can differentiate in monolayer culture to 
express markers of differentiation such as involucrin, filaggrin 
and keratin 10. W12E and NIKS16 also synthesize HPV late 
proteins E4 and L1, suggesting completion of the viral life 
cycle [30, 36].
SRSFs are transcriptionally upregulated at late stages of HPV 
infection [30, 36, 39, 40] and SRSFs have well- documented 
roles in positively and negatively controlling splicing of HPV 
RNAs encoding the viral early and late proteins [6, 8, 30, 41]. 
SRSFs can have cytoplasmic as well as nuclear functions 
[13, 42]. We examined the location of the HPV- upregulated 
SRSF protein SRSF1 in undifferentiated (early life cycle) and 
differentiated (late life cycle) HPV16- infected W12E cells. 
SRSF2 and SRSF7 were used as negative controls. Although 
SRSF2 is upregulated by HPV E2 [30], it is confined to the 
nucleus [43] while SRSF7 is not regulated by HPV16 [30]. 
SRSF1 was located mainly in the nucleus of undifferentiated 
W12E cells (Fig. 1a). In contrast, while SRSF2 and 7 remained 
in the nucleus when the cells were differentiated, SRSF1 was 
present in both the nucleus and the cytoplasm (Fig.  1b), 
Fig. 1. SRSF1 is present in the cytoplasm in differentiated HPV- infected 
keratinocytes. (a) Confocal microscopy analysis of the location of SR 
proteins SRSF1, SRSF2 and SFSR7 in undifferentiated W12E (HPV16- 
infected) keratinocytes. (b) Analysis of the location of SR proteins 
SRSF1, SRSF2 and SFSR7 in differentiated W12E (HPV16- infected) 
keratinocytes. (c) Analysis of the location of SRSF1 and SFSR7 in 
undifferentiated and differentiated HaCaT keratinocytes (HPV- negative). 
(d) Analysis of the location of SRSF1 and SRSF2 in undifferentiated 
NIKS (HPV- negative) and NIKS16 (HPV16- infected) keratinocytes. (e) 
Analysis of the location of SRSF1 and SRSF2 in differentiated NIKS 
(HPV- negative) and NIKS16 (HPV16- infected) keratinocytes. Cells were 
stained with involucrin to show differentiation. No involucrin staining 
was detected in undifferentiated cells. Nuclei were counterstained with 
DAPI (DAPI Merge). Bar, 20 µm.
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indicating a differentiation- specific mechanism of relocation 
to the cytoplasm. Similar to SRSF7, SRSF1 was detected in the 
nucleus and was absent from the cytoplasm of HPV- negative 
undifferentiated and differentiated HaCaT keratinocytes 
(Fig. 1c). To determine if the relocation was due to HPV 
infection we compared SR protein location in NIKS and 
NIKS16 cells. SRSF1 and SRSF2 were located mainly in the 
nucleus of undifferentiated NIKS and NIKS16 cells (Fig. 1d). 
While SRSF2 was detected mainly in the nucleus of both cell 
types, SRSF1 was found in the cytoplasm of differentiated 
NIKS16 (although cytoplasmic relocation was not as striking 
as in W12E cells) but not in the HPV- negative NIKS cells 
(Fig. 1e). Involucrin levels were detected only in differentiated 
cell populations as expected. Together, these data suggest that 
HPV16 infection causes SRSF1 protein to accumulate in the 
cytoplasm of differentiated keratinocytes.
SRSF1 phosphorylation is altered by HPV infection
The nuclear location of SRSF proteins is positively controlled 
by phosphorylation of their serine–arginine (RS) domains, 
but cycles of phosphosphorylation/dephosphorylation are 
also important for SRSF function [13]. We reported previously 
that differentiated HPV- positive keratinocytes expressed 
more hyperphosphorylated SRSF1 than undifferentiated 
keratinocytes [36]. Using Mab96, which detects all forms of 
SRSF1, the protein was detected in the nuclear fractions from 
both NIKS and NIKS16 cells, but more SRSF1 was detected 
in differentiated (D) cells (Fig. 2a, lanes 3 and 4). U2AF was 
used as a nuclear splicing factor loading control. There was 
very little phosphorylated SRSF1 detected in the cytoplasm 
of HPV- negative or positive undifferentiated (U) NIKS cells 
(Fig. 2b, lanes 1 and 2). Upon long exposure of the western blot 
Fig. 2. SRSF1 phosphorylation is upregulated by HPV16 infection in a differentiation- specific manner. (a) Western blot analysis of total 
SRSF1 (Mab96) levels in the nuclei of undifferentiated (U) and differentiated (D) NIKS (HPV- negative) and NIKS16 (HPV16- positive) 
keratinocytes. Nuclear U2AF65 was used as a loading control. (b) Hyper- and hypophosphorylated SRSF1 levels (Mab96 reactivity 
indicated with vertical lines) in the cytoplasm of undifferentiated (U, lanes 1 and 2) and differentiated (D, lanes 3 and 4) NIKS (HPV- 
negative) and NIKS16 (HPV16- positive) keratinocytes. Lane 5 shows nuclear SRSF1 from undifferentiated NIKS16 cells. Short (top panel) 
and long (second top panel) exposures of the western blot are shown to visualize cytoplasmic phosphorylated SRSF1. GAPDH was used 
as a cytoplasmic loading control. U2AF65 was used as a nuclear loading control. Involucrin staining showed that NIKS and NIKS16 cells 
were differentiated (lanes 3 and 4). Nuclear and cytoplasmic fractions were prepared from the same cells. Involucrin is a cytoplasmic 
protein so acts also as a differentiation control for the western blots in (a) (lanes 3 and 4). (c) Hyper- and hypophosphorylated SRSF1 
levels (Mab96) in the nuclei (nuc) and cytoplasm (cyto) of differentiated NIKS (HPV- negative) and NIKS16 (HPV16- positive) keratinocytes. 
Lane 1, asterisk: five times the quantity of protein extract was applied to this lane. +CIP, protein extracts were digested with calf intestinal 
alkaline phosphatase to show the migration of hypophosphorylated SRSF1. (d) Quantification of the relative levels of phosphorylated 
nuclear SRSF1 in NIKS compared to NIKS16 cells. The data show the mean and sd from three separate experiments.
5Mole et al., Journal of General Virology 2020
some SRSF1 was detected in the cytoplasm of differentiated 
(D) NIKS cells (Fig. 2b, lane 3). However, cytoplasmic SRSF1 
levels were markedly increased in differentiated (D) NIKS16 
cells (Fig. 2b, lane 4). The increased, cytoplasmic SRSF1 was 
phosphorylated because it had very similar mobility in the 
western blotted gel to hyperphosphorylated nuclear SRSF1 
(Fig. 2B, lane 5). GAPDH was used as a loading control for 
cytoplasmic fractions (Fig. 2b, lanes 1–4). U2AF was used as 
a loading control for the nuclear fraction in lane 5. Involu-
crin antibody reactivity demonstrated differentiation of the 
protein extracts in lanes 3 and 4. To confirm that SRSF1 was 
phosphorylated, we carried out dephosphorylation of differ-
entiated cell extracts using calf intestinal alkaline phosphatase 
(+CIP) and used a gradient gel that was able to separate SRSF1 
isoforms. In order to visualize cytoplasmic SRSF1 from NIKS 
cells, five times the amount of protein lysate was loaded in 
lane 1 of Fig. 2c (asterisk). In the cytoplasmic compartment 
of both NIKS and NIKS16 cells, only hyperphosphorylated 
SRSF1 was detected (Fig.  2c, compare lanes 1 and 5 and 
lanes 2 and 6). Hyper- and hypo- phosphorylated SRSF1 was 
detected in the nucleus of NIKS (Fig. 2c, compare lanes 3 and 
7) and NIKS16 cells (Fig. 2c, compare lanes 4 and 8), which 
also contained more SRSF1 overall. Quantification of relative 
levels of phosphorylated nuclear SRSF1 from three separate 
experiments revealed a 3.5- fold increase in differentiated 
NIKS16 compared to NIKS cells (Fig. 2d). Taken together, 
these data suggest that HPV infection upregulates SRSF1 
protein phosphorylation and increases cytoplasmic SRSF1 
levels during the productive stages of the HPV life cycle in 
differentiated keratinocytes.
SRPK1 levels are increased by HPV infection
SRPK1 activity is required for nuclear SRSF import and 
function so we investigated whether, similar to its substrate 
SRSF proteins, SRPK1 was upregulated by HPV16 infec-
tion. Protein lysates were prepared from undifferentiated 
(U) and differentiated (D), HPV16- negative and -posi-
tive NIKS keratinocytes. Western blot analysis showed 
reduced levels of SRPK1 in differentiated compared to 
undifferentiated virus- negative cells (Fig.  3a, b, NIKS). 
In contrast, SRPK1 levels were increased in differentiated 
HPV16- positive NIKS cells (Fig. 3a, b, NIKS16). Similarly, 
compared to undifferentiated HPV16- infected W12E cells, 
levels of SRPK1 increased when the cells were differentiated 
(Fig. 3c). Increased involucrin levels indicated when NIKS, 
NIKS16 and W12E cells were differentiated (Fig. 3a, c). The 
cellular location of SRPK1 during the HPV16 life cycle 
was examined by confocal microscopy in HPV16- positive 
epithelial cells. In undifferentiated (U) and differentiated 
(D) NIKS16 cells, SRPK1 was located in both the nuclear 
and the cytoplasmic compartments, but in differentiated 
Fig. 3. SRPK1 is greatest in differentiated HPV16- positive keratinocytes. (a) Western blot analysis of SRPK1 levels in undifferentiated 
(U) and differentiated (D) NIKS (HPV- negative) and NIKS16 cells (HPV16- positive) keratinocytes. (b) Graph showing quantification of 
SRPK1 levels relative to the GAPDH control. The mean and sd of three separate experiments are shown. (c) Western blot analysis of 
SRPK1 levels in undifferentiated (U) and differentiated (D) W12E (HPV16- positive) keratinocytes. In (a) and (c) involucrin was used to 
show keratinocyte differentiation and GAPDH was used as a loading control. (d) Confocal microscopy analysis of SRPK1 location in 
undifferentiated and differentiated NIKS16 keratinocytes. (e) Confocal microscopy analysis of SRPK1 location in undifferentiated (U) and 
differentiated (D) W12E (HPV16- positive) keratinocytes. DAPI merge, nuclei were counterstained with DAPI. Bar, 10 µm. (f) Graph showing 
quantification of cytoplasmic compared to total cellular SRPK1 levels in undifferentiated and differentiated NIKS16 cells. Twelve cells 
were measured in each case and the mean and sem are shown.
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cells a greater proportion of SRPK1 was present in the 
cytoplasm (Fig. 3d). A very similar result was found for 
W12E cells (Fig. 3e). Quantification of levels of cytoplasmic 
SRPK1 in undifferentiated versus differentiated NIKS16 
cells revealed a highly significant increase due to HPV16 
infection (Fig. 3f). Thus, SRPK1 levels and subcellular loca-
tion is controlled by HPV16 infection during keratinocyte 
differentiation.
HPV E2 upregulates SRPK1
Late viral regulatory proteins E2 and E4 have been shown 
to have an association with SRSF proteins and SRPK1: 
HPV16 E4 can bind SRPK1, which suggests E4 could be 
in complex with SR proteins, while the viral replication/
transcription factor E2 has SRSF protein- like functions and 
activates expression of SRSF1, 2 and 3 [29, 44–46]. There-
fore, we investigated if either E2 or E4 was responsible for 
the HPV- associated changes we observed in SRPK1 levels 
or subcellular location. First, we tested if E2 could increase 
SRPK1 levels. We compared SRPK1 levels in U2OS cells 
stably transfected with vector alone (U2OSV) and in two 
E2- positive U2OS clones, U2OSA4 and U2OSB1, which 
express different levels of HPV16 E2 (Fig.  4a) [35, 36]. 
SRPK1 expression responded to increased levels of E2 and 
was markedly upregulated in the B1 clone with the highest 
level of E2 expression (Fig.  4a). Confocal microscopy 
analysis of SRPK1 confirmed upregulation in U2OSB1 cells 
(Fig. 4b). Overexpression of E2 can drive cells into senes-
cence or apoptosis [47]. Although U2OS cells are relatively 
resistant to these processes, the U2OSB1 cells appeared 
more rounded than the low E2- expressing cells (U2OSA4) 
or the E2- negative control cells (U2OSV), probably due to 
E2 toxicity, and this may influence SRPK1 location. Quan-
tification of SRPK1 levels in the nucleus compared to the 
entire cell confirmed that increased SRPK1 was present 
in the nucleus of cells expressing E2 (Fig. 4c). These data 
suggest that HPV16 regulates expression levels of SRPK1 
through the viral transcription factor E2.
To investigate if HPV16 E4 controlled SRPK1, we overex-
pressed E4 in HeLa cervical epithelial cells (we were unable 
to obtain sufficient expression levels in HaCaT or NIKS 
cells). Confocal microscopy analysis revealed that there 
was no apparent change in the subcellular location or 
levels of SRPK1 between cells expressing or not expressing 
E4 [compare the two cells indicated with an asterisk 
(E4- positive) and an arrow (E4- negative) in Fig. 4d].
SRPK1 is required to maintain levels of SRSF1 in 
differentiated HPV16-positive keratinocytes
HPV- mediated increases in SRPK1 levels could be respon-
sible for causing the increased levels of phosphorylated 
SRSF1 that we observed in differentiated HPV- infected 
cells. siRNA depletion experiments revealed that loss of 
SRPK1 resulted in reduced total SRSF1 levels in differ-
entiated NIKS16 cells. The effect on SRSF1 was specific 
because levels of another SR protein that is a much poorer 
substrate for SRPK1, SRSF2, did not change (Fig. 5a). Simi-
larly, treatment of cells with the specific SRPK1 inhibitor 
SRPIN340 also caused a significant decrease in total 
SRSF1 levels (Fig. 5b, c), but there was no change in SRSF2 
levels (Fig. 5b, d). Moreover, SRSF1 levels decreased in an 
SRPIN340 dose- dependent manner (Fig. 5c). To assess the 
effect of SRPIN340 on SRSF1 activity, we examined total 
Fig. 4. SRPK1 expression is regulated by HPV16 E2 but not by HPV16 E4. (a) Western blot analysis of levels of SRPK1 in U2OS cells stably 
transfected with an empty vector (U2OSV), or in two different U2OS cell clones stably transfected with an E2 expression vector (U2OSA4, 
U2OSB1). Tubulin was used as a loading control. (b) Confocal microscopy analysis of SRPK1 location in the three U2OS cell clones. Bar, 
20 µm. (c) Graph showing quantification of nuclear as a percentage of total cellular SRPK1 levels in U2OSV and U2OSB1 cell clones. Five 
cells were measured in each case and the mean and sem are shown. (d) Confocal microscopy analysis of SRPK1 (red staining) location 
in HeLa cells overexpressing E4 (green staining, white asterisk) compared to untransfected cells (white arrowhead). DAPI merge, nucleic 
were stained with DAPI (blue). Bar, 10 µm.
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SRSF1 (Mab96) and pSRSF1 (Mab104) levels in NIKS16 
cells in the presence of the drug, or the drug vehicle, DMSO, 
or upon treatment with SRPIN349, a compound that can 
bind SRPK1 but does not inhibit its kinase activity [48]. 
Levels of total SRSF1 were again reduced in the presence 
of the kinase inhibitor, but there was a greater reduction in 
pSRSF1 compared to controls (Fig. 5e, f). This confirms that 
SRPK1 controls SRSF1 phosphorylation, and therefore its 
activity, in HPV16- infected keratinocytes.
These results suggest that SRPK1 is required to maintain 
levels of SRSF1 in differentiated HPV- infected keratinocytes. 
Taken together, our data reveal an HPV16- regulation of the 
SRPK1–SR protein control axis.
Fig. 5. SRPK1 is required for SRSF1 phosphorylation in differentiated HPV16- positive keratinocytes. (a) Western blot analysis of total 
cellular SRSF1 levels (Mab96) in NIKS16 (HPV16- infected) cells treated with a control siRNA (Cntrl) or upon siRNA depletion of SRPK1 
(SRPK1). The middle lane of the three is blank (–). GAPDH was used as a loading control. SRSF2 is shown as a control for an SR protein 
that is not significantly phosphorylated by SRPK1. Involucrin is shown as a control for keratinocyte differentiation. (b) Western blot 
analysis of total SRSF1 levels (Mab96) in NIKS16 cells untreated (Mock) or treated with the SRPK1 inhibitor SRPIN340 (10 µM, 50 µM) 
or with the vehicle, DMSO. SRPK1 levels are unaffected by drug treatment. SRSF2 is shown as a control for an SR protein that is not 
significantly phosphorylated by SRPK1. Involucrin is shown as a control for keratinocyte differentiation. Tubulin was used as a loading 
control. (c) Graph of relative levels of SRSF1 in untreated, DMSO- treated and SRPIN340- treated NIKS16 cells. (d) Graph of relative levels 
of SRSF2 in untreated, DMSO- treated and SRPIN340- treated NIKS16 cells. Western blot analysis of total (Mab96) and phosphor- SRSF1 
(Mab104) levels in differentiated NIKS16 keratinocytes treated with drug vehicle, DMSO, or 10 µM SRPIN340 or SRPIN349, a similar 
compound that can bind SRPK1 but cannot inhibit its activity. (f) Quantification of the data in (e). The data are representative of two 
separate experiments.
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DISCUSSION
We reported previously the upregulation of SRSF1 in differen-
tiated W12 cells and in the upper epithelial layers of low- grade 
cervical lesions [36, 39]. Moreover, we showed that HPV16 
and 31 E2 transcription factor was able to trans- activate the 
promoter of the gene encoding SRSF1 [30, 40]. Here we show 
that SRSF1 has increased cytoplasmic abundance in differen-
tiated HPV16- infected keratinocytes. The change in location 
of a portion of the protein may be related to HPV infection 
because more cytoplasmic SRSF1 was detected in NIKS16 
compared to HPV- negative NIKS cells. Nuclear and cyto-
plasmic levels of hyperphosphorylated SRSF1 were increased 
in differentiated HPV16- positive NIKS cells compared to 
HPV- negative NIKS cells. Although analysis of the relative 
levels of SRSF1 in both cellular compartments showed that the 
majority of the protein was located in the nucleus, the pres-
ence of increased hyperphosphorylated cytoplasmic SRSF1 
suggests that the SRSF nuclear import machinery may be 
saturated by the increased amounts of the protein present in 
differentiated HPV- infected keratinocytes. Alternatively, late 
in the virus life cycle SRSF1 could be actively retained in the 
cytoplasm where it might have a specific cytoplasmic func-
tion, for example control of mRNA stability or translation.
SRPKs transduce growth signals to positively or negatively 
control SR protein phosphorylation and splicing [13]. SR 
proteins are imported into the nucleus following SRPK1- 
mediated phosphorylation, while cycles of phosphorylation/
dephosphorylation regulate the various functions of SR 
proteins [13]. We have demonstrated that HPV16 upregulates 
the SR protein kinase, SRPK1, in a keratinocyte differentiation 
stage- specific manner. While SRPK1 levels were reduced upon 
differentiation of HPV16- negative keratinocytes, levels of the 
kinase were two- fold greater in differentiated HPV- infected 
cells compared to undifferentiated cells. Both nuclear and 
cytoplasmic SRPK1 were detected in HPV- infected keratino-
cytes. However, cytoplasmic levels of SRPK1 were increased 
in differentiated W12E cells and NIKS16 cells, compared to 
undifferentiated cells. This suggests that HPV infection can 
cause changes in the levels and subcellular distribution of 
SRPK1 similar to those of its substrate SRSF1.
HPV replication in the differentiating epithelium is subject 
to control by metabolic signalling alterations. For example, 
the Akt signalling pathway is activated by HPV E7 [49, 50], 
which is expressed during the early phase of infection in the 
lower layers of the epithelium [51]. Akt induces autophos-
phorylation of SRPK1 to allow its translocation to the nucleus 
where it upregulates SR protein phosphorylation and splicing 
in concert with a nuclear SR protein kinase, Clk [52]. This 
suggests that lower levels of Akt could result in a block to 
SRPK1 import into the nucleus. Expression of E7 is reduced 
in more differentiated HPV- infected keratinocytes, and this 
may explain the apparent increase in cytoplasmic SRPK1 
levels in differentiated HPV16- infected cells. However, this 
could also be due to SRPK1 upregulation by HPV16 E2, 
which is expressed in keratinocytes in the mid- to upper 
epithelial layers [53]. E2 can regulate many cellular proteins 
at the transcriptional level [54] but direct E2 stimulation of 
SRPK1 expression remains to be explored. Analysis of the 
SRPK1 promoter sequence revealed a sequence ACCGTT-
GAAACGGT. The nucleotides in bold conform to the 
consensus alpha E2 binding site sequence. However, although 
the nucleotide sequence of the central part of the E2 binding 
motif (underlined) can be variable, it is too long by 2 nt. 
Further experiments are required to see if E2 can bind directly 
to the SRPK1 promoter. Alternatively, it could bind indirectly 
via transcription factor partners such as SP1, which is known 
to activate SRPK1 expression [55].
Increased levels of SRSFs and SRPK1 have been detected in 
tumour cells [13]. Although the mechanisms behind this 
are unclear, it has been postulated that increased levels of 
splicing factors result in altered alternative splicing to create 
a tumorigenic transcriptome and/or by promoting genome 
instability [21]. One explanation for the increase in SRPK1 
levels in HPV- infected cells could be that these cells represent 
tumour progression. We consider that this is unlikely because 
we could detect markers of keratinocyte differentiation in 
differentiated W12 and NIKS16 cells, which are not usually 
detected in tumour cells [56]. Moreover, these cells formed 
discrete colonies in monolayer culture and were able to form 
differentiated tissues in 3D organotypic raft cultures (data not 
shown). On the other hand, W12 cells were isolated from a 
low- grade cervical lesion [38], while clone 2L NIKS16 cells 
form a CIN1- like lesion when grown in 3D raft culture [34]. 
Therefore, the presence of these factors in the cytoplasm 
of HPV16- positive cells could be an early event in tumour 
progression.
Increased SRPK1 levels could be beneficial to viral replica-
tion. Activation of the SRPK1–SR protein axis late in HPV 
infection could be important for correct expression of alter-
natively spliced late mRNAs that encode the virus capsid 
proteins [4, 6]. To test the role of SRPK1 in regulating SRSF1 
during the HPV16 life cycle we depleted levels of the kinase 
in differentiated NIKS16 keratinocytes using siRNA and also 
inhibited the kinase with SRPIN340, a specific inhibitor of 
SRPK1 [48]. Both treatments reduced the levels of total SRSF1 
but drug treatment also reduced phospho- SRSF1 protein 
levels. A previous study in colorectal cancer cells revealed 
that reducing SRPK1 levels by drug or siRNA treatment 
caused SRSF1 to be degraded in the cytoplasm [57]. SRSF1 
mRNA levels were unaltered upon siRNA or drug inhibition 
of SRPK1 in HPV- infected keratinocytes (data not shown), 
suggesting that SRSF1 may undergo proteasomal degrada-
tion in the cytoplasm of SRPK1- depleted, or inhibited, non- 
tumour keratinocytes. Therefore, SRSF1 phosphorylation in 
the cytoplasm, driven by HPV16 infection, may aid stabi-
lization of the protein and its accumulation in that cellular 
compartment.
HPV gene expression is positively and negatively controlled 
largely at various post- transcriptional levels, particularly 
through control of viral pre- mRNA splicing [3, 4]. Because 
SR splicing factors are required for generation of HPV 
mRNAs, and SRPK1 is required to regulate these proteins, 
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HPV gene regulation could be achieved by viral stimula-
tion of these factors. The HPV life cycle is tightly linked to 
keratinocyte differentiation, so the differentiation- specific 
upregulation of SR proteins and their kinase that we have 
uncovered strengthens this hypothesis. Possible HPV regula-
tion of Clk, the nuclear SR protein kinase and partner protein 
of SRPK1, and the role of Clk in the HPV life cycle, remain 
to be explored. It is of note that viral stimulation of SRPK1 
activity could affect the HPV life cycle in other ways such as 
phosphorylation of viral proteins including E2 [28], which 
we have shown upregulates SRPK1 expression, suggesting a 
feedback mechanism. SRPK1 can phosphorylate HBV core 
protein, a prerequisite for encapisdation of viral DNA [24]. 
HPV capsid proteins, which are phosphorylated, are synthe-
sized in differentiated keratinocytes. A recent study showed 
capsid protein phosphorylation was essential for virus entry, 
although the kinase has not been identified [58]. It is tempting 
to speculate that SRPK1 could be a candidate kinase for this 
event. If SRPK1 proves to be important for HPV replication, 
anti- splicing drugs such as SRPIN340 could be developed as 
novel antivirals against HPV.
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